Deferasirox (Exjade):: A new iron chelator

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2006年 / 48卷 / 1233期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [21] Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload.
    Cappellini, M. D.
    Giardina, P.
    Porter, J.
    Coates, T.
    Della Porta, M. G.
    Siegel, J.
    Glimm, E.
    Ford, J.
    Cappellini, Maria Dominica
    BLOOD, 2006, 108 (11) : 501A - 501A
  • [22] Deferasirox: Oral, once daily iron chelator - an expert opinion
    Agarwal, M. B.
    INDIAN JOURNAL OF PEDIATRICS, 2010, 77 (02): : 185 - 191
  • [23] Deferasirox: Oral, once daily iron chelator — an expert opinion
    M.B. Agarwal
    The Indian Journal of Pediatrics, 2010, 77 : 185 - 191
  • [24] Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
    Saeki, Issei
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Takami, Taro
    Maeda, Masaki
    Fujisawa, Koichi
    Iwamoto, Takuya
    Matsumoto, Toshihiko
    Hidaka, Isao
    Ishikawa, Tsuyoshi
    Uchida, Koichi
    Tani, Kenji
    Sakaida, Isao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (40) : 8967 - 8977
  • [25] Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients.
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    Capdeville, Renaud
    BLOOD, 2006, 108 (11) : 503A - 503A
  • [26] Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
    Issei Saeki
    Naoki Yamamoto
    Takahiro Yamasaki
    Taro Takami
    Masaki Maeda
    Koichi Fujisawa
    Takuya Iwamoto
    Toshihiko Matsumoto
    Isao Hidaka
    Tsuyoshi Ishikawa
    Koichi Uchida
    Kenji Tani
    Isao Sakaida
    World Journal of Gastroenterology, 2016, 22 (40) : 8967 - 8977
  • [27] The iron chelator deferasirox protects mice from mucormycosis through iron starvation
    Ibrahim, Ashraf S.
    Gebermariam, Teclegiorgis
    Fu, Yue
    Lin, Lin
    Husseiny, Mohamed I.
    French, Samuel W.
    Schwartz, Julie
    Skory, Christopher D.
    Edwards, John E., Jr.
    Spellbergl, Brad J.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (09): : 2649 - 2657
  • [28] Exjade® (Deferasirox): Iron in Balance - Therapy Management in MDS- and Thalassemia-Patients
    Meyer, Ina
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2014, 41 (02)
  • [29] Transfusion Dependent MDS-Patients benefit from Iron Chelation with Exjade®(Deferasirox)
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2014, 41 (06) : 471 - 471
  • [30] Patients can derive treble Benefit from Iron Chelate Therapy with Exjade® (Deferasirox)
    Meyer, Ina
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2012, 39 (05)
12345